Skip to main content

Table 4 Long term results of current studies on SBRT for liver metastases

From: Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up

Author, (reference) design study, year Patients with liver metastases Dose (Gy/ fr) Follow-up (median) Local control (%) Overall survivall (%) Toxicity ≥G3
1-year 5-yeras 1-year 5-years
Hoyer, [15] Phase II, 2006 44 45Gy/3fr 4.3 years 79% at 2 years 67% 13% 48%
Fode, [18] Retrospective. 2015 212 (321 tot oligometastatic patient) BED10 = 72–195 Gy 5 years 91% 80% 23% 4%
(Not specified for liver metastases) (Not specified for liver metastases)
Goodman, [39] Retrospective 2016 81 32–60/3–5 fr 2.25 years 96% 91% at 4 years 89.9% 28% at 4 years 4.9%
McPartlin, [28] Phase I-II, 2017 51 22.7–62.1 Gy /6 fr 2.3 years 49.8% 26% at 4 years 63% 9% at 4 years 3%
Joo, [29] Retrospective 2017 70 45-60Gy/3–4fr 2.8 years 93% 68% at 3 years 75% at 2 years 0%
Mendez Romero [40] Retrospective, 2017 40 37.5 Gy / 3fr 2.2 years 96% 66% at 3 years 95% 48% at 3 years 7.5%
50.25 Gy / 3 fr 90% 81% at 3 years 94% 65% at 3 years
Present study 61 75Gy/3 fr (82% of lesions) 67.5–52.5 Gy/3fr (18% of lesions) 6.1 years 94% 78% 85.2% 18% 1%